• Business News

    Luminar Provides Business Update and First Quarter Results

    Luminar Technologies, Inc. (“Luminar” or the “Company”) (NASDAQ: LAZR), the global leader in automotive lidar hardware and software technology, today announced a quarterly business update and financials for the first quarter ended March 31, 2021. “We’ve remained relentlessly focused on execution, hitting our key product, commercial, production and financial targets so far. This puts Luminar on track to meet or beat our 2021 company-level milestones from the beginning of the year, as we continue to extend our technology, product, and market leadership positions.” — Austin Russell, Founder & CEO Execution: Product, Industrialization, and Series Production Luminar continues to scale its  

    Comments Off on Luminar Provides Business Update and First Quarter Results
  • Business & Finance

    Valneva Reports Q1 2021 Financial Results and Business Update

    Excellent progress on clinical programs in the first quarter of 2021 for: VLA15, currently the only clinical stage vaccine candidate against Lyme disease VLA2001, currently the only inactivated, adjuvanted vaccine candidate for COVID-19 in clinical trials in Europe: Initiation of pivotal Phase 3 clinical trial Participation in the world’s first COVID-19 vaccine booster trial in the UK Publication of Phase 1/2 results VLA1553, currently the only Phase 3 chikungunya vaccine program worldwide Successful Nasdaq listing (Q2 event); $107.6 million of gross proceeds raised in a US initial public offering and a concurrent private placement in Europe Cash and cash equivalents  

    Comments Off on Valneva Reports Q1 2021 Financial Results and Business Update
  • Business & Finance

    Ionis reports first quarter 2021 financial results and recent business achievements

    On track to achieve 2021 guidance Webcast today, May 5, 2021, at 11:30 a.m. Eastern Time CARLSBAD, Calif., May 5, 2021 /PRNewswire/ — Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today reported its financial results for the first quarter of 2021 and recent business highlights. (PRNewsfoto/Ionis Pharmaceuticals, Inc.) “In the first quarter, we took important steps to maximize the value of our wholly owned pipeline. We recently initiated pivotal studies with our wholly owned FUS-ALS and Alexander disease programs. We delivered positive results from our IONIS-PKK-LRx program, demonstrating its potential to change the standard of care for patients with hereditary  

    Comments Off on Ionis reports first quarter 2021 financial results and recent business achievements
  • Business & Finance

    Moderna Reports First Quarter Fiscal Year 2021 Financial Results and Provides Business Updates

    SARS-CoV-2 Variant Booster Program Update: Single booster dose of 50 µg of mRNA-1273 or mRNA-1273.351 increased neutralizing titers against SARS-CoV-2 and two Variants of Concern (B.1.351, P.1) in previously vaccinated clinical trial participants TeenCOVE Study Update: Initial analysis of the Phase 2/3 TeenCOVE study of mRNA-1273 showed vaccine efficacy against COVID-19 of 96{a25bda0f8ab6dac90e68079d6f038584ef6ac53f1f4621de3ad526e35cd6c0d6}; mRNA-1273 was generally well tolerated with no serious safety concerns identified to date 2021 and 2022 Vaccine Manufacturing: Company increased its 2021 supply forecast to between 800 million and 1 billion doses; Company making investments to increase global supply for COVID-19 Vaccine to up to  

    Comments Off on Moderna Reports First Quarter Fiscal Year 2021 Financial Results and Provides Business Updates
  • Business & Finance

    Aldeyra Therapeutics Reports First-Quarter 2021 Financial Results and Recent Business Highlights

    Recently Announced Phase 3 INVIGORATE Clinical Trial Results Indicated Statistically Significant Activity of Reproxalap in Ocular Itching and Redness Associated with Allergic Conjunctivitis Top-Line Results from Phase 3 TRANQUILITY and TRANQUILITY-2 Trials of Reproxalap in Dry Eye Disease Expected in the Second Half of 2021 Initial Phase 2 Clinical Trial Results for ADX-629, a Novel Orally Available Systems-Based RASP Inhibitor with Potential Broad Applicability Across Immune-Mediated Diseases, Expected in the Second Half of 2021 Raised Gross Proceeds of $125 Million Before Deduction of Underwriting Discounts and Commissions, in Underwritten Public Offering Projected Cash Runway Through 2023, Including Potential New Drug  

    Comments Off on Aldeyra Therapeutics Reports First-Quarter 2021 Financial Results and Recent Business Highlights